BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic (CDx) for WILSERDLY (giredestrant) in combination with everolimus. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for WILSERDLY in combination with everolimus and is